Openly accessible

Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery

Xiang, Dongxi, Shigdar, Sarah, Bean, Andrew G, Bruce, Matthew, Yang, Wenrong, Mathesh, Motilal, Wang, Tao, Yin, Wang, Tran, Phuong Ha Lien, Shamaileh, Hadi Al, Barrero, Roberto A, Zhang, Pei-Zhuo, Li, Yong, Kong, Lingxue, Liu, Ke, Zhou, Shu-Feng, Hou, Yingchun, He, Aina and Duan, Wei 2017, Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery, Theranostics, vol. 7, no. 17, pp. 4071-4086, doi: 10.7150/thno.20168.

Attached Files
Name Description MIMEType Size Downloads
xiang-transformingdoxorubicin-2017.pdf Published version application/pdf 2.14MB 167

Title Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery
Author(s) Xiang, Dongxi
Shigdar, SarahORCID iD for Shigdar, Sarah orcid.org/0000-0001-8084-8447
Bean, Andrew G
Bruce, Matthew
Yang, WenrongORCID iD for Yang, Wenrong orcid.org/0000-0001-8815-1951
Mathesh, Motilal
Wang, Tao
Yin, WangORCID iD for Yin, Wang orcid.org/0000-0002-5665-3559
Tran, Phuong Ha LienORCID iD for Tran, Phuong Ha Lien orcid.org/0000-0001-8463-7516
Shamaileh, Hadi Al
Barrero, Roberto A
Zhang, Pei-Zhuo
Li, Yong
Kong, LingxueORCID iD for Kong, Lingxue orcid.org/0000-0001-6219-3897
Liu, Ke
Zhou, Shu-Feng
Hou, Yingchun
He, Aina
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Journal name Theranostics
Volume number 7
Issue number 17
Start page 4071
End page 4086
Total pages 16
Publisher Ivyspring International Publisher
Place of publication Sydney, N.S.W.
Publication date 2017
ISSN 1838-7640
Keyword(s) doxorubicin
cancer stem cell killer
Summary Chemotherapy-resistant cancer stem cells (CSCs) are a major obstacle to the effective treatment of many forms of cancer. To overcome CSC chemo-resistance, we developed a novel system by conjugating a CSC-targeting EpCAM aptamer with doxorubicin (Apt-DOX) to eliminate CSCs. Incubation of Apt-DOX with colorectal cancer cells resulted in high concentration and prolonged retention of DOX in the nuclei. Treatment of tumour-bearing xenograft mice with Apt-DOX resulted in at least 3-fold more inhibition of tumour growth and longer survival as well as a 30-fold lower frequency of CSC and a prolonged longer tumourigenic latency compared with those receiving the same dose of free DOX. Our data demonstrate that a CSC-targeting aptamer is able to transform a conventional chemotherapeutic agent into a CSC-killer to overcome drug resistance in solid tumours.
Language eng
DOI 10.7150/thno.20168
Field of Research 111201 Cancer Cell Biology
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2017, Ivyspring International Publisher
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30103338

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 29 times in TR Web of Science
Scopus Citation Count Cited 32 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 503 Abstract Views, 170 File Downloads  -  Detailed Statistics
Created: Tue, 17 Oct 2017, 08:18:43 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.